MHRA Strengthens Safety Warnings Following Botulism Risks
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued strengthened safety warnings for all botulinum toxin type A products. This regulatory action follows reports of rare cases of iatrogenic botulism—botulism caused by medical treatment—linked to the use of these substances. While botulinum toxin is widely utilized for both medical conditions and cosmetic procedures, the MHRA is emphasizing that the toxin’s effects can, in rare instances, spread beyond the injection site, leading to a serious and potentially life-threatening condition.
The agency has collaborated with manufacturers to update product information and patient leaflets to clearly articulate these risks. Officials stress that while these products are effective when used correctly, it is vital for both patients and healthcare professionals to remain vigilant for symptoms of botulism, which can emerge within days or up to four weeks following an injection.
Recognizing the Symptoms of a Medical Emergency
Botulism is a rare but severe condition that attacks the nervous system, potentially leading to paralysis that can spread throughout the body. If left untreated, the toxin can affect the muscles responsible for breathing.
According to the NHS and the MHRA, individuals who have recently received botulinum toxin treatments should seek immediate medical attention if they experience any of the following symptoms:
- Difficulty swallowing
- Slurred speech or difficulty speaking
- Breathing difficulties
- Muscle weakness, particularly in the face
- Blurred or double vision
- Drooping eyelids
- Dry mouth
- Constipation
Dr. Martin Bewley, a Consultant in Health Protection at the UK Health Security Agency (UKHSA), advised that anyone experiencing these symptoms after a recent procedure should contact NHS 111 or seek immediate medical care. “It is important to get checked out so you can have peace of mind and treatment if needed,” he noted.
Investigations into Unlicensed and Counterfeit Products
The MHRA has issued a stern warning regarding the dangers of unlicensed and counterfeit botulinum toxin products. Investigations by the MHRA’s Criminal Enforcement Unit are currently underway following a spike in hospital admissions reported over the last year. Recent data indicates that 38 cases of botulism poisoning were reported in England between June 4 and July 14, 2025, with evidence suggesting the use of unlicensed, Botox-like products. These cases were reported in the north-east, the east of England, and the East Midlands.
According to Dr. Alison Cave, MHRA Chief Safety Officer, products obtained outside of regulated supply chains do not meet UK safety and quality standards. “Public safety is a top priority for the MHRA,” Dr. Cave stated, adding that the use of unlicensed products means there are no safeguards to ensure the items meet the agency’s standards, which can endanger the health of those who receive them.
Ensuring Safety in Cosmetic Procedures
Health officials emphasize that the risk of adverse reactions may be higher for patients with specific underlying conditions, such as neurological disorders, or a history of dysphagia (difficulty swallowing) or aspiration. Risks also increase when high doses are administered, or when products are used outside of their licensed indications or injected into unapproved sites.
To mitigate these dangers, the NHS and the MHRA urge the public to take specific precautions:
- Verify the Practitioner: Ensure the person administering the injection is appropriately qualified and registered. The NHS provides online resources to assist in choosing an appropriate prescriber.
- Confirm Licensing: Always verify that the product being used is authorised for use in the UK.
- Avoid Unregulated Sources: Do not purchase or accept injections from sources outside of regulated supply chains.
The NHS notes that while prompt hospital treatment—which may include the use of anti-toxins and respiratory support—can aid recovery, the medication cannot reverse muscle weakness or paralysis that has already occurred. Recovery from breathing difficulties, in particular, can take up to a year.
Patients who suspect they have experienced a side effect from these treatments are encouraged to report their experiences through the MHRA’s Yellow Card scheme. Botulinum toxin type A remains a prescription-only medicine in the UK, authorised for conditions including muscle spasms, hyperhidrosis, and overactive bladder, as well as cosmetic uses.
Find more reporting in our Health section.
Related reading